Continuous treatment improves survival of newly diagnosed multiple myeloma patients achieving complete response: data from 5 phase III trials including young and elderly patients

P. Di Bartolomeo; M. Offidani; P. Corradini; M. Boccadoro; H. Lokhorst; P. Sonneveld; S. Zweegman; M. Salvini; F. Gay; R. Mina; L. el Jarari; C. Cerrato; M. Pellegrino; D.B. Yehuda; F. Patriarca; L. Catalano; N. Cascavilla; G. Gaidano; T. Gugielmelli; A. Spencer; M.T. Petrucci; A. Palumbo; F. Di Raimondo; R. Hajek; M. Gambella; G. Semenzato

doi:https://doi.org/10.1016/j.clml.2015.07.193

Continuous treatment improves survival of newly diagnosed multiple myeloma patients achieving complete response: data from 5 phase III trials including young and elderly patients

P. Di Bartolomeo, M. Offidani, P. Corradini, M. Boccadoro, H. Lokhorst, P. Sonneveld, S. Zweegman, M. Salvini, F. Gay, R. Mina, L. el Jarari, C. Cerrato, M. Pellegrino, D.B. Yehuda, F. Patriarca, L. Catalano, N. Cascavilla, G. Gaidano, T. Gugielmelli, A. SpencerM.T. Petrucci, A. Palumbo, F. Di Raimondo, R. Hajek, M. Gambella, G. Semenzato

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Introduction: Several studies demonstrated that continuous therapy (CT) prolonged progression-free survival (PFS); conflicting data exist about overall survival (OS) for patients eligible and ineligible for autologous stem cell transplantation (ASCT). CT in patients with a sensitive disease is a matter of debate. We conducted a pooled analysis to clarify the role of CT in patients with a complete response (CR). Methods: Newly diagnosed myeloma patients enrolled in 5 phase III trials were analysed. Three trials included ASCT eligible patients: RV-MM-209 [MPR vs Mel200, followed by lenalidomide vs no maintenance), RV-MM-EMN-441 (CRD vs Mel200, followed by lenalidomide vs lenalidomide-prednisone maintenance) and HOVON65/GMMG-HD4 (PAD vs VAD, followed by bortezomib or thalidomide maintenance). Two studies enrolled elderly patients: GIMEMA-MM0305 (VMPT-VT vs VMP) and EMN01 (MPR vs CPR vs Rd, followed by lenalidomide vs lenalidomide-prednisone maintenance). The primary objective was to evaluate the impact of maintenance on PFS and OS in CR patients. Univariate analyses of OS and PFS were performed. Response was treated as time-dependent variable in a landmark analysis (at 4 months). Results: 2792 patients were retrospectively analysed. 2330 patients received maintenance, 503 (21%) of them achieved a CR (378 eligible vs 125 ineligible for ASCT) before maintenance. After a median follow-up of 47 months, a significant 5-year OS (79% vs 59%; HR0.5, p

Original language	English
Pages (from-to)	e54
Journal	Clinical Lymphoma Myeloma and Leukemia
Volume	15
DOIs	https://doi.org/10.1016/j.clml.2015.07.193
Publication status	Published - 27 Sept 2015

Access to Document

https://doi.org/10.1016/j.clml.2015.07.193

http://www.mendeley.com/research/continuous-treatment-improves-survivalofnewlydiagnosed-multiple-myelomapatients-achieving-completere

Cite this

Di Bartolomeo, P., Offidani, M., Corradini, P., Boccadoro, M., Lokhorst, H., Sonneveld, P., Zweegman, S., Salvini, M., Gay, F., Mina, R., el Jarari, L., Cerrato, C., Pellegrino, M., Yehuda, D. B., Patriarca, F., Catalano, L., Cascavilla, N., Gaidano, G., Gugielmelli, T., ... Semenzato, G. (2015). Continuous treatment improves survival of newly diagnosed multiple myeloma patients achieving complete response: data from 5 phase III trials including young and elderly patients. Clinical Lymphoma Myeloma and Leukemia, 15, e54. https://doi.org/10.1016/j.clml.2015.07.193

@article{d1df8289cb6340fdb34e48bf86ee0281,

title = "Continuous treatment improves survival of newly diagnosed multiple myeloma patients achieving complete response: data from 5 phase III trials including young and elderly patients",

abstract = "Introduction: Several studies demonstrated that continuous therapy (CT) prolonged progression-free survival (PFS); conflicting data exist about overall survival (OS) for patients eligible and ineligible for autologous stem cell transplantation (ASCT). CT in patients with a sensitive disease is a matter of debate. We conducted a pooled analysis to clarify the role of CT in patients with a complete response (CR). Methods: Newly diagnosed myeloma patients enrolled in 5 phase III trials were analysed. Three trials included ASCT eligible patients: RV-MM-209 [MPR vs Mel200, followed by lenalidomide vs no maintenance), RV-MM-EMN-441 (CRD vs Mel200, followed by lenalidomide vs lenalidomide-prednisone maintenance) and HOVON65/GMMG-HD4 (PAD vs VAD, followed by bortezomib or thalidomide maintenance). Two studies enrolled elderly patients: GIMEMA-MM0305 (VMPT-VT vs VMP) and EMN01 (MPR vs CPR vs Rd, followed by lenalidomide vs lenalidomide-prednisone maintenance). The primary objective was to evaluate the impact of maintenance on PFS and OS in CR patients. Univariate analyses of OS and PFS were performed. Response was treated as time-dependent variable in a landmark analysis (at 4 months). Results: 2792 patients were retrospectively analysed. 2330 patients received maintenance, 503 (21%) of them achieved a CR (378 eligible vs 125 ineligible for ASCT) before maintenance. After a median follow-up of 47 months, a significant 5-year OS (79% vs 59%; HR0.5, p",

author = "{Di Bartolomeo}, P. and M. Offidani and P. Corradini and M. Boccadoro and H. Lokhorst and P. Sonneveld and S. Zweegman and M. Salvini and F. Gay and R. Mina and {el Jarari}, L. and C. Cerrato and M. Pellegrino and D.B. Yehuda and F. Patriarca and L. Catalano and N. Cascavilla and G. Gaidano and T. Gugielmelli and A. Spencer and M.T. Petrucci and A. Palumbo and {Di Raimondo}, F. and R. Hajek and M. Gambella and G. Semenzato",

year = "2015",

month = sep,

day = "27",

doi = "https://doi.org/10.1016/j.clml.2015.07.193",

language = "English",

volume = "15",

pages = "e54",

journal = "Clinical Lymphoma Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

}

Di Bartolomeo, P, Offidani, M, Corradini, P, Boccadoro, M, Lokhorst, H, Sonneveld, P , Zweegman, S, Salvini, M, Gay, F, Mina, R, el Jarari, L, Cerrato, C, Pellegrino, M, Yehuda, DB, Patriarca, F, Catalano, L, Cascavilla, N, Gaidano, G, Gugielmelli, T, Spencer, A, Petrucci, MT, Palumbo, A, Di Raimondo, F, Hajek, R, Gambella, M & Semenzato, G 2015, 'Continuous treatment improves survival of newly diagnosed multiple myeloma patients achieving complete response: data from 5 phase III trials including young and elderly patients', Clinical Lymphoma Myeloma and Leukemia, vol. 15, pp. e54. https://doi.org/10.1016/j.clml.2015.07.193

Continuous treatment improves survival of newly diagnosed multiple myeloma patients achieving complete response: data from 5 phase III trials including young and elderly patients. / Di Bartolomeo, P.; Offidani, M.; Corradini, P. et al.
In: Clinical Lymphoma Myeloma and Leukemia, Vol. 15, 27.09.2015, p. e54.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Continuous treatment improves survival of newly diagnosed multiple myeloma patients achieving complete response: data from 5 phase III trials including young and elderly patients

AU - Di Bartolomeo, P.

AU - Offidani, M.

AU - Corradini, P.

AU - Boccadoro, M.

AU - Lokhorst, H.

AU - Sonneveld, P.

AU - Zweegman, S.

AU - Salvini, M.

AU - Gay, F.

AU - Mina, R.

AU - el Jarari, L.

AU - Cerrato, C.

AU - Pellegrino, M.

AU - Yehuda, D.B.

AU - Patriarca, F.

AU - Catalano, L.

AU - Cascavilla, N.

AU - Gaidano, G.

AU - Gugielmelli, T.

AU - Spencer, A.

AU - Petrucci, M.T.

AU - Palumbo, A.

AU - Di Raimondo, F.

AU - Hajek, R.

AU - Gambella, M.

AU - Semenzato, G.

PY - 2015/9/27

Y1 - 2015/9/27

N2 - Introduction: Several studies demonstrated that continuous therapy (CT) prolonged progression-free survival (PFS); conflicting data exist about overall survival (OS) for patients eligible and ineligible for autologous stem cell transplantation (ASCT). CT in patients with a sensitive disease is a matter of debate. We conducted a pooled analysis to clarify the role of CT in patients with a complete response (CR). Methods: Newly diagnosed myeloma patients enrolled in 5 phase III trials were analysed. Three trials included ASCT eligible patients: RV-MM-209 [MPR vs Mel200, followed by lenalidomide vs no maintenance), RV-MM-EMN-441 (CRD vs Mel200, followed by lenalidomide vs lenalidomide-prednisone maintenance) and HOVON65/GMMG-HD4 (PAD vs VAD, followed by bortezomib or thalidomide maintenance). Two studies enrolled elderly patients: GIMEMA-MM0305 (VMPT-VT vs VMP) and EMN01 (MPR vs CPR vs Rd, followed by lenalidomide vs lenalidomide-prednisone maintenance). The primary objective was to evaluate the impact of maintenance on PFS and OS in CR patients. Univariate analyses of OS and PFS were performed. Response was treated as time-dependent variable in a landmark analysis (at 4 months). Results: 2792 patients were retrospectively analysed. 2330 patients received maintenance, 503 (21%) of them achieved a CR (378 eligible vs 125 ineligible for ASCT) before maintenance. After a median follow-up of 47 months, a significant 5-year OS (79% vs 59%; HR0.5, p

AB - Introduction: Several studies demonstrated that continuous therapy (CT) prolonged progression-free survival (PFS); conflicting data exist about overall survival (OS) for patients eligible and ineligible for autologous stem cell transplantation (ASCT). CT in patients with a sensitive disease is a matter of debate. We conducted a pooled analysis to clarify the role of CT in patients with a complete response (CR). Methods: Newly diagnosed myeloma patients enrolled in 5 phase III trials were analysed. Three trials included ASCT eligible patients: RV-MM-209 [MPR vs Mel200, followed by lenalidomide vs no maintenance), RV-MM-EMN-441 (CRD vs Mel200, followed by lenalidomide vs lenalidomide-prednisone maintenance) and HOVON65/GMMG-HD4 (PAD vs VAD, followed by bortezomib or thalidomide maintenance). Two studies enrolled elderly patients: GIMEMA-MM0305 (VMPT-VT vs VMP) and EMN01 (MPR vs CPR vs Rd, followed by lenalidomide vs lenalidomide-prednisone maintenance). The primary objective was to evaluate the impact of maintenance on PFS and OS in CR patients. Univariate analyses of OS and PFS were performed. Response was treated as time-dependent variable in a landmark analysis (at 4 months). Results: 2792 patients were retrospectively analysed. 2330 patients received maintenance, 503 (21%) of them achieved a CR (378 eligible vs 125 ineligible for ASCT) before maintenance. After a median follow-up of 47 months, a significant 5-year OS (79% vs 59%; HR0.5, p

U2 - https://doi.org/10.1016/j.clml.2015.07.193

DO - https://doi.org/10.1016/j.clml.2015.07.193

M3 - Article

SN - 2152-2650

VL - 15

SP - e54

JO - Clinical Lymphoma Myeloma and Leukemia

JF - Clinical Lymphoma Myeloma and Leukemia

ER -

Di Bartolomeo P, Offidani M, Corradini P, Boccadoro M, Lokhorst H, Sonneveld P et al. Continuous treatment improves survival of newly diagnosed multiple myeloma patients achieving complete response: data from 5 phase III trials including young and elderly patients. Clinical Lymphoma Myeloma and Leukemia. 2015 Sept 27;15:e54. doi: https://doi.org/10.1016/j.clml.2015.07.193